Evaluation of the immunogenicity of Meningococcal B (4CMenB) and Meningococcal ACWY (MenACWY Conjugate) vaccination in a population with HIV at 18 and 30 months after two doses of vaccine (ProPositive Follow—up). 

Status: Closed to Recruitment

Population: Adults living with HIV

Disease group: Meningococcal disease

Funder: GSK

Sponsor: St George’s, University of London 

Principal Investigator: Dr. Catherine Cosgrove

Study Aims 

This study aims to evaluate the long-term immune response following two doses of meningococcal vaccines (4CMenB, Bexero® and MenACWY-CRM197, Menveo®) 18-months and 30-months post vaccination.  

What does participating in the study involve?  

People living with HIV (PLWHIV) have increased risk of invasive meningococcal disease. Several meningococcal vaccines are licensed in the UK, however there is little data on their immunological protection in PLWHIV. 

 This is a follow-up study to the Propositive trial run at the Vaccine Institute, where 55 adults 18-45 who are HIV+ were vaccinated with two doses of 4MenB and MenACWY vaccines. 

Participants who completed the original trial were invited to take part in the follow-up study, where blood samples to evaluate immune response are taken approximately 1.5 and 2.5 years after their second dose of vaccine.